Acute Myeloid Leukemia Clinical Trial

Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia

Summary

This is a pilot study designed to identify the effect of daunorubicin-cytarabine liposome (CPX-351) in combination with a FLT3-inhibitor (midostaurin) as induction and consolidation therapy for patients with high-risk FLT3 mutated acute myeloid leukemia (AML) and subsequent CD34+-selected allogeneic stem cell transplant from HLA compatible related or unrelated donors.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patients must have a Karnofsky (adult) Performance Status of at least 70%.
Patients must have adequate organ function

Exclusion Criteria:

Female patients who are pregnant or breast-feeding
Active viral, bacterial or fungal infection
Patient seropositive for Human Immunodeficiency Virus (HIV-I /II); Human T-Cell Lymphotrophic Virus (HTLV -I /II)
Presence of leukemia in the Central Nervous System (CNS).

Study is for people with:

Acute Myeloid Leukemia

Phase:

Phase 1

Estimated Enrollment:

20

Study ID:

NCT04982354

Recruitment Status:

Recruiting

Sponsor:

Guenther Koehne

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Miami Cancer Institute at Baptist Health of South Florida
Miami Florida, 33176, United States More Info
Guenther Koehne, MD, PhD
Contact
786-596-2000
[email protected]
Guenther Koehne, MD, PhD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Acute Myeloid Leukemia

Phase:

Phase 1

Estimated Enrollment:

20

Study ID:

NCT04982354

Recruitment Status:

Recruiting

Sponsor:


Guenther Koehne

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.